Microfluidic screening reveals SARS-CoV-2 antibody candidate

Microfluidic screening technologies have been used to discover a promising antibody candidate against SARS-CoV-2 and the South African variant.

Antibody against SARS-CoV-2

Using microfluidic, single-cell molecular cloning and screening technologies to enable antibody repertoire mining and discovery, Memo Therapeutics has identified a promising antibody candidate against SARS-CoV-2 and the South African variant (B.1.351).

The discovery platform captures and preserves entire B-cell repertoires from any donor species and any B-cell type in recombinant form for display using mammalian cells. The antibody repertoires are subsequently screened in single-cell format using microfluidic screening technology that can assess millions of candidate antibodies directly in functional assays, resulting in recombinant clonal cell lines expressing monoclonal antibodies (mAbs) with the desired functional properties.

The company also reports that a new human-derived antibody has also shown efficacy against both original SARS-CoV-2 as well as the UK variant (B.1.1.7). The antibody, named MTX-COVAB, is now being prepared for clinical evaluation.

This business is also collaborating with Serum Institute India and other academic partners in Austria, Brazil and South Africa to source patient samples in the coming weeks to enable the isolation of promising, effective antibodies against each of the variants. According to Memo Therapeutics, this can be achieved in as little as three weeks from receiving the blood sample.

“Addressing SARS-CoV-2 variants remains a global challenge and one that will remain. Vaccines will not always be effective against all variants, so the ability of our technology to rapidly identify active antibodies could form an additional strategy to combat the spread of these mutant strains,” said Dr Christoph Esslinger, Chief Scientific Officer and co-founder of Memo Therapeutics.

“Memo’s ability to discover potent antibodies against COVID-19 variants in such a short period of time highlights the power and broad applicability of our technology,” said Dr Karsten Fischer, Chief Executive Officer of Memo Therapeutics. “We look forward to working with colleagues in India, Austria, South Africa and Brazil to apply this potent approach to these difficult to control new strains.”